Catherine Mattes is an associate in Quinn Emanuel’s New York office. Ms. Mattes’ practice primarily focuses on complex litigation in the chemical, pharmaceutical, and biotechnology areas. Ms. Mattes has extensive experience in patent litigation and counseling in a broad range of technologies. She has experience in all stages of patent litigation, including pre-suit investigation, fact and expert discovery, trial, post-trial, and appeals. Ms. Mattes has represented innovative brand name pharmaceutical companies in complex Hatch-Waxman litigations against multiple defendants.
Her recent representations include litigations concerning: Invokana®/Invokamet® (a treatment for type II diabetes); Abraxane® (a treatment for pancreatic and breast cancers); Omeprazole OTC (a treatment for heartburn); NuvaRing® (a contraceptive treatment); Revlimid® (a treatment for multiple myeloma and myelodysplastic syndromes); Nuedexta® (a treatment for pseudobulbar affect); and Xyrem® (a treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy).
Ms. Mattes’ practice also includes counseling clients regarding patent portfolio evaluation, including conducting diligences regarding the patentability of inventions, the validity of patents and the freedom to operate new technologies. Her practice also involves the negotiation and preparation of licensing and settlement agreements.
Ms. Mattes received her J.D. from Brooklyn Law School, where she interned with Magistrate Judge Kevin Fox and District Court Judge Alvin Hellerstein in the Southern District of New York. She performed graduate-level research and earned a M.S. in Biomedical Engineering from Columbia University in 2006. She earned a B.S. in Biological and Environmental Engineering from Cornell University in 2005.
- Brooklyn Law School
- (J.D., 2011)
- Columbia University
- (M.S., Biomedical Engineering, 2006)
- Cornell University
- (B.S., Biological and Environmental Engineering, 2005)